Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes

Cheng, Shi Bin; Yang, Yan; Zhou, Yong; Xiang, Wei; Yao, Hua; Ma, Ling

doi:10.3892/etm.2018.5855

Cited by 4 publications

(6 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, use of 20 mg/dL UA had no effect on this outcome. This finding is similar to that of our previous study (12) as well as other studies that have shown that normal serum UA concentration (5 mg/dL -------------------------------------------------- SIFT DESK in our study) could assist the body antioxidative system in preventing oxidative damage (11,14). Cells treated with UA demonstrated a decreased rate of apoptosis compared with model cells, in particular, cells treated with 5 mg/dL and 10 mg/dL of UA.…”

Section: Discussionsupporting

confidence: 94%

“…The method used to develop a steatosis cell model was similar to that used in our previous study, described in detail elsewhere (12). Briefly, we prepared a 10-mM working solution by mixing 28.25 mg of oleic acid (OA) and 4 mg of NaOH in 10 ml of ultrapure water; this working solution was added to a standard medium to prepare sodium oleate medium with OA concentration of 0.3 mM.…”

Section: Steatosis Cell Model Development and Ua Treatmentmentioning

confidence: 99%

“…UA is associated with obesity (8), type 2 diabetes (9), and chronic kidney disease (10); nevertheless, it remains an antioxidant within the human body (11). Our previous study (12) has demonstrated that UA at a dose of 5 mg/dL and 10 mg/dL could play an antioxidative role in an in vitro model of steatosis in L-02 cells. In this study, we examined the impact of UA on mitochondrial electron transport chain (ETC) parameters and its role in alleviating ETC inhibition to decrease the production of ROS, leading to reduction of OS in a steatosis model of L-02 cells.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The impact of uric acid treatment on mitochlondria morphology and function in a steatosis model of L-02 cells

Ma¹,

Xiang²,

Cheng³

et al. 2020

SDRP JFST

Self Cite

View full text Add to dashboard Cite

Background and objectives: Nonalcoholic fatty liver disease (NAFLD) is one of the most prevalent chronic diseases worldwide. Oxidative stress (OS) is a major contributor toward NAFLD development, while mitochondria play a central role in OS. Our previous study has shown that uric acid (UA), as a dual function metabolite, could alleviate OS. This study examined the impact of UA on mitochondria morphology and function in a model of steatosis using L-02 cells to explore the pathogenesis of NAFLD. Methods: The L‑02 hepatocyte cell line was used to develop a steatosis cell model via 0.3 mM oleic acid (OA) over 24 h, subsequently treated with uric acid (UA) dose of 5, 10, and 20 mg/dL for 24, 48, and 72 h, respectively. The fluorescence intensity of reactive oxygen species (ROS), apoptosis rate, and activity of Succinate dehydrogenase(SDH), cytochrome oxidas(CCO), and adenosine triphosphate(ATP) synthase in electron transport chain (ETC), as well as the content of ATP and 8-OH-dG were examined; ultrastructure was observed under an electron microscope. Results: Treatment with UA at a concentration of 5 and 10 mg/dL decreased the rate of ROS production, apoptosis, and 8-OH-dG concentration, while supporting ATP recovery, and SDH activity in the steatosis model cell. It also promoted lipid droplet metabolism; however, the recovery of mitochondria morphology was not obvious. Conclusions: Treatment with UA dose of 5 and 10 mg/dL could protect mitochondria from OS damage. Future research requires a more stable and effective model. keywords : electron transport chain, oxidative stress, nonalcoholic fatty liver disease

show abstract

Section: Discussionsupporting

confidence: 94%

Section: Steatosis Cell Model Development and Ua Treatmentmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The impact of uric acid treatment on mitochlondria morphology and function in a steatosis model of L-02 cells

Ma¹,

Xiang²,

Cheng³

et al. 2020

SDRP JFST

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is mainly decomposed from nucleic acids by enzymes or from other purine compounds metabolized by cells. UA is a reducing substance in the human body, participating in redox reactions and scavenging oxygen free radicals, thereby inhibiting oxidative stress [27,28]. Several studies have reported that serum UA is involved in the pathogenesis of OP by affecting oxidative stress and inflammatory cascades [29].…”

Section: Discussionmentioning

confidence: 99%

Integrated proteomics and metabolomics analysis of lumbar in a rat model of osteoporosis treated with Gushukang capsules

Lin

Xie

et al. 2022

BMC Complement Med Ther

View full text Add to dashboard Cite

Background Gushukang (GSK) capsules are a Chinese patented medicine that is widely used in clinics for the treatment of osteoporosis (OP). Animal experiments have revealed that the bone mineral density of osteoporotic rats increase after treatment with GSK capsules. However, the specific mechanism and target of GSK in the treatment of osteoporosis are unclear. Further studies are needed. Methods Metabolomics (GC/MS) and proteomics (TMT-LC-MC/MC) with bioinformatics (KEGG pathway enrichment), correlation analysis (Pearson correlation matrix), and joint pathway analysis (MetaboAnalyst) were employed to determine the underlying mechanisms of GSK. The differential expression proteins were verified by WB experiment. Results The regulation of proteins, i.e., Cant1, Gstz1, Aldh3b1, Bid, and Slc1a3, in the common metabolic pathway of differential proteins and metabolites between GSK/OP and OP/SHAM was corrected in the GSK group. The regulation of 12 metabolites (tyramine, thymidine, deoxycytidine, cytosine, L-Aspartate, etc.) were differential in the common enrichment metabolic pathway between GSK /OP and OP/SHAM. Differential proteins and metabolites jointly regulate 11 metabolic pathways, such as purine metabolism, pyrimidine metabolism, histidine metabolism, beta-alanine metabolism, and so on. Conclusion GSK may protect bone metabolism in osteoporotic rats by affecting nucleotide metabolism, amino acid metabolism, and the immune system.

show abstract

“…However, when present at abnormally high levels it may become a risk factor for many metabolic syndromes and diseases (12)(13)(14)(15). SUA is a powerful scavenger of free radicals, which may contribute as an endogenous systemic antioxidant in protecting the bones from deterioration (16). Many experimental and epidemiological studies provided conflicting conclusions about the relation between SUA and bone health (17,18).…”

Section: Introductionmentioning

confidence: 99%

Serum Uric Acid Level Is Positively Associated With Higher Bone Mineral Density at Multiple Skeletal Sites Among Healthy Qataris

et al. 2021

View full text Add to dashboard Cite

BackgroundOxidative stress has been implicated as a fundamental mechanism in the decline of bone mass. Although serum uric acid (SUA) has potent antioxidant properties, the findings of many epidemiological and experimental studies couldn’t draw a clear conclusion on the relation between SUA and bone health. We aim to investigate the association between SUA and bone mineral density (BMD) at different skeletal sites among healthy Qataris.MethodologyA cross-sectional analysis including total-body and site-specific bone mineral density scores and other serological markers of 2981 healthy Qatari adults (36.4 ± 11.1 years) from the Qatar biobank database was conducted. The study participants were divided into quartiles based on the level of SUA, and the BMD was measured using dual-energy X-ray absorptiometry (DXA). Multiple regression analyses were applied to investigate the association between SUA and BMD adjusting for multiple confounding factors.ResultsHigh levels of SUA were significantly associated with the increased bone mineral density of the total body and at site-specific skeletal locations after adjusting for age and gender (p-value < 0.001). Further adjustment for body mass index (BMI), smoking, vitamin D, alkaline phosphatase, and estimated glomerular filtration rate (eGFR) levels attenuated the association but the association remained significant for individuals with high SUA levels (p-value ≤ 0.01).The association between SUA and BMD was not significant in non-obese, females, young adults, and smokers. However, no interaction was found between SUA and age, gender, BMI and smoking.ConclusionHigher SUA levels are associated with a high bone density among healthy Qatari adults. However, such observation demands further investigations to outline the underlying mechanisms.

show abstract

Influence of different concentrations of uric acid on oxidative stress in steatosis hepatocytes

Cited by 4 publications

References 37 publications

The impact of uric acid treatment on mitochlondria morphology and function in a steatosis model of L-02 cells

The impact of uric acid treatment on mitochlondria morphology and function in a steatosis model of L-02 cells

Integrated proteomics and metabolomics analysis of lumbar in a rat model of osteoporosis treated with Gushukang capsules

Serum Uric Acid Level Is Positively Associated With Higher Bone Mineral Density at Multiple Skeletal Sites Among Healthy Qataris

Contact Info

Product

Resources

About